背景:白细胞介素-17(IL-17)单克隆抗体药物在银屑病的治疗中越来越重要。但目前尚不清楚不同种族的疗效是否相同。
目的:探讨IL-17抑制剂在白种人和亚洲人短期疗效的差异。
方法:估计组间的合并对数风险比(logRR)。对logRR进行了荟萃回归分析,以白种人患者的比例为协变量。通过特异性IL-17抑制剂进行亚组分析。
结果:在1,569项潜在相关研究中,纳入16项随机对照试验(RCTs).对于12周时的银屑病面积和严重程度指数75(PASI75)反应,亚洲组和高加索组的汇总logRR分别为2.81(95%CI:2.27-3.35,p<0.001)和2.93(95%CI:2.71-3.16,p<0.001),分别,表明亚洲人和白种人之间的疗效没有显着差异。荟萃回归分析未显示白种人的比例与效应大小相关(β=0.3203,p=0.334)。在亚组分析中,苏金单抗的比较结果与主要分析一致。
结论:仅探讨了短期疗效。亚洲国家的数据有限。
结论:IL-17抑制剂治疗银屑病的短期疗效在白种人和亚洲人之间无显著差异。
背景:PROSPERO,标识符CRD42020201994,https://www.crd.约克。AC.英国/普华永道/。
BACKGROUND: Interleukin-17 (IL-17) monoclonal antibody drugs have been increasingly significant in the treatment of psoriasis, but it is not clear whether the efficacy is equivalent across ethnicities.
OBJECTIVE: To explore the differences of short-term efficacy of IL-17 inhibitors between Caucasians and Asians.
METHODS: The pooled log risk ratio (logRR) between the groups was estimated. The meta-regression analysis on the logRR was performed, with the proportion of Caucasian patients as the covariate. The subgroup analysis was performed by specific IL-17 inhibitors.
RESULTS: Of the 1,569 potentially relevant studies, sixteen randomized controlled trials (RCTs) were included. For the Psoriasis Area and Severity Index 75 (PASI 75) response at week 12, the pooled logRR of the Asian group and the Caucasian group was 2.81 (95% CI: 2.27-3.35, p < 0.001) and 2.93 (95% CI: 2.71-3.16, p < 0.001), respectively, indicating no significant difference of efficacy between Asians and Caucasians. The meta-regression analysis did not show an association of the proportion of Caucasians with the effect size (β = 0.3203, p = 0.334). In the subgroup analysis, the comparison results of secukinumab were consistent with the main analysis.
CONCLUSIONS: Only the short-term efficacy was explored. The data from Asian countries were limited.
CONCLUSIONS: The short-term efficacy of IL-17 inhibitors in the treatment of psoriasis has no significant difference between Caucasians and Asians.
BACKGROUND: PROSPERO, identifier CRD42020201994, https://www.crd.york.ac.uk/prospero/.